+++ Mögen Sie uns? Unseren Service, unsere Produkte, unser Pricing? Dann freuen wir uns über Ihr Lob und Ihre Wahl von BNP Paribas zu Ihrem Lieblings-Emittenten +++-w-
27.09.2021 13:00

Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program


NEW HAVEN, Conn., Sept. 27, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of a clinical trial of verdiperstat in multiple system atrophy (MSA).  Verdiperstat did not statistically differentiate from placebo on the prespecified primary efficacy measure, nor on the key secondary efficacy measures. Initial analysis of safety data was consistent with the overall profile of verdiperstat from prior clinical trial experience. Additional analyses are still pending, and full study results will be presented at an upcoming scientific meeting.

(PRNewsfoto/Biohaven Pharmaceutical Holding)

Irfan Qureshi, M.D., Vice President of Neurology at Biohaven commented, "While we are disappointed that verdiperstat did not demonstrate efficacy for the treatment of MSA, Biohaven remains committed to fighting on behalf of people living with neurodegenerative diseases. There are currently no approved disease modifying therapies for MSA and we must continue to advance the science to improve treatment outcomes for patients suffering from this disease. We are extremely grateful to the international MSA community – especially the patients and their families, investigators and their teams, and patient advocacy groups – who made the trial possible."

Verdiperstat is an investigational first-in-class, potent, selective, brain-penetrant, and irreversible myeloperoxidase (MPO) enzyme inhibitor that Biohaven is developing for the treatment of neurodegenerative diseases. Verdiperstat may help preserve neurons through inhibition of MPO-induced pathological oxidative stress and further inflammation that contribute to cellular injury in neurodegenerative disease.

Although the mechanism of action for verdiperstat, myeloperoxidase inhibition, was shown not to be effective for MSA, the rationale of targeting brain inflammation remains strong in other disease states.  An ongoing clinical trial evaluating the efficacy of verdiperstat in amyotrophic lateral sclerosis (ALS) is being conducted in collaboration with the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and is expected to complete enrollment in the fourth quarter of 2021.

About MSA
MSA is a rare, rapidly progressive, severely debilitating, and fatal neurodegenerative disease that leads to death within a median of 6-10 years after the onset of symptoms. Manifestations of MSA can include urinary and sexual dysfunction, dizziness and fainting due to low blood pressure (orthostatic hypotension), and motor impairments such as tremor, rigidity, unsteady gait, and difficulty speaking and swallowing. The most common causes of death in MSA are infection and cardiopulmonary complications. Currently, patients receive only symptomatic and palliative therapies as there are no disease-modifying treatments and no cure for MSA. 

About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute and preventive treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, Alzheimer's disease, and spinocerebellar ataxia; and MPO inhibition for neurodegenerative disease, including ALS. More information about Biohaven is available at www.biohavenpharma.com.

Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. The use of certain words, including the "expect" and "will" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans and objectives disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements, including uncertainties relating to the future clinical success of verdiperstat. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 1, 2021, and in Biohaven's subsequent filings with the Securities and Exchange Commission. The forward-looking statements are made as of this date and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Biohaven Contact:
Vlad Coric, M.D.
Chief Executive Officer

Media Contact:
Mike Beyer
Sam Brown Inc.


Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-provides-update-on-phase-3-trial-and-multiple-system-atrophy-msa-program-301385193.html

SOURCE Biohaven Pharmaceutical Holding Company Ltd.

Nachrichten zu Biohaven Pharmaceutical Holding Co Ltd Registered Shs

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Biohaven Pharmaceutical Holding Co Ltd Registered Shs

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
25.06.2019Biohaven Pharmaceutical BuyCanaccord Adams
04.03.2019Biohaven Pharmaceutical BuyNeedham & Company, LLC
02.07.2018Biohaven Pharmaceutical BuyNeedham & Company, LLC
05.04.2018Biohaven Pharmaceutical Equal WeightBarclays Capital
22.02.2018Biohaven Pharmaceutical BuyCanaccord Adams
25.06.2019Biohaven Pharmaceutical BuyCanaccord Adams
04.03.2019Biohaven Pharmaceutical BuyNeedham & Company, LLC
02.07.2018Biohaven Pharmaceutical BuyNeedham & Company, LLC
22.02.2018Biohaven Pharmaceutical BuyCanaccord Adams
15.12.2017Biohaven Pharmaceutical BuyCanaccord Adams
05.04.2018Biohaven Pharmaceutical Equal WeightBarclays Capital

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Biohaven Pharmaceutical Holding Co Ltd Registered Shs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen

Meistgelesene Biohaven Pharmaceutical News

Keine Nachrichten gefunden.
Weitere Biohaven Pharmaceutical News
Börse Stuttgart Anlegerclub

Biohaven Pharmaceutical Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

US-Börsen unentschlossen -- DAX geht tiefer in den Feierabend -- Deutsche Bank steigert Quartalsgewinn -- BASF hebt Jahresziele erneut an -- Spekulation um Ionos-IPO -- Alphabet, Microsoft im Fokus

EU-Kommission will Übernahme von ARM durch NVIDIA genauer prüfen. Spotify zieht neue Abonnenten an. 'Dreamliner'-Probleme brocken Boeing Quartalsverlust ein. Chip-Krise lässt Gewinn von General Motors einbrechen. Coca-Cola wächst kräftig. AMD-Aktie stärker: Wachstumssprung in Zeiten der Chip-Knappheit. US-Expertengremium spricht sich für BioNTech-Impfung für Kinder aus.


Würden Sie eine verpflichtende Corona-Impfung gutheißen?

finanzen.net zero
finanzen.net zero



Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln